Stay updated with breaking news from Patrick Vermersch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF.
THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate
Press release content from Business Wire. The AP news staff was not involved in its creation.
DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis IMCY-MS-001 study aims to determine safe...
Darmstadt: Merck, a science and technology company, has recently announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and...